NSCLC: Transgene launches cancer combo tes...Transgene has started Phase II efficacy testing of its therapeutic cancer vaccine TG4010 and Bristol-Myers Squibbs checkpoint inhibitor Opdivo (nivolumab) in non-squamous non-small cell lung cancer … more ➔
Allogenic stem cell transplant safe in hea...Belgian cell therapeutics specialist TiGenix NV announced positive top-line one-year results from its CAREMI stem cell study in acute myocardial infarction. more ➔
Pharnext partners with Galapagos Neurodegeneration specialist Pharnext SA and autoimmune disease expert Galapagos NV have inked an R&D contract in order to expand Pharnexts pleotherapy approach to new indications. more ➔
BerGenBio plans IPO and partners with MSD Norwegian BerGenBio ASA said it will go public at Oslo Børs and partnered with Merck & Co. for conducting Phase II combination studies of its oral Axl kinase blocker BGB324 with Mercks PD-1 inhibitor … more ➔
Breath Therapeutics cashes in €43,5mInhaled lung therapeutics specialist Breath Therapeutics Holding BV closed a Series A financing led by Gimv and Sofinnova. more ➔
PwC reports high productivity of UK Life S... The UKs Life Sciences sector is more than twice as productive as the UK average, says a new analyst report. However, it doesn’t come close to the productivity in Switzerland or other leading life … more ➔
Roche restarts pivotal Gantenerumab testsMorphoSys AG has announced that its partner Roche plans to start two further pivotal Phase III studies with its licensed Alzheimers antibody Gantenerumab. more ➔
Sanofi and AZ ink €600m deal for RSV jab Sanofis vaccine arm Sanofi Pasteur has inked a deal with AstraZenecas biologics subsidiary MedImmune totaling €615m to acquire co-development rights for MEDI8897, a jab to prevent respiratory … more ➔
Nestle researchers link IBS to anxietyResearchers at Nestlé Research Center in Lausanne and Canadian collaborators have found that the microbiome of irritable bowel syndrome patients affects their susceptibility for anxiety disorders. more ➔
FDA grants Priority Review to avelumab Avelumab, Merck KGaAs and Pfizers Phase III checkpoint inhibitor, has been granted Priority Review from the US Food and Drug Administration in urothelial carcinoma patients who progressed on or … more ➔
